Uncategorized

san diego skyline

ASH 2023: PSI Team Spotlight

ASH 2023 is coming up December 9 – 12, and our team is excited to join the conversation with hematology sponsors and partners like you. Stop by Booth #3352 for a chance (or schedule a meeting here) to speak with PSI experts helping to support hematology-oncology and hemophilia innovators across the globe. Meet our team members who are packing their bags for San Diego.

Vince Calderon
Director Project Management

Vince serves as a Director and supervisor of Project Management, overseeing PSI’s team of Project Management staff and several studies in oncology and hematology. Vince has been with PSI since December 2019, and is based in Texas. He has over 19 years’ clinical research experience, 15 years of project management experience, and has delivered 20+ oncology studies in both solid tumors and hematology-oncology.

Vince has professional affiliations with the Project Management Institute in the US and has been a certified Project Management Professional since 2012.

Rhonda Critchlow
Senior Director, Operations

Rhonda Critchlow, Senior Director of Therapeutic Strategy, currently oversees all of PSI’s core indications, and specializes in operational strategy within oncology and radiopharmaceuticals. With over 25 years of research experience, she provides valuable leadership and management working both regionally and globally.

Overseeing the therapeutic strategy department, which includes our Site Support Specialist, Rhonda brings guidance and oversight to specialty vendor management, patient recruitment and retention for our sponsors.

Prior to working at PSI, her experience includes working within oncology research as a Coordinator and Director, CRA, Clinical Trial Manager, Head of Monitoring and Vice President of Early Phase Oncology before joining PSI. Rhonda also has experience working with general radiology and nuclear medicine in large hospital organizations, providing valuable input for clinical development, study management and operational considerations.

Colleen Ring
Associate Director, Feasibility

Colleen Ring, PhD, Associate Director, Feasibility, has worked in the clinical research industry for the past 12 years. Prior to transitioning to the clinical research field, Colleen was a senior research scientist, specializing in multiple signaling pathways (e.g. TGFb, Tyrosine Kinases, Rho/Rac GTPases) across a broad range of areas, including oncology. As a leader within PSI’s global feasibility team, Colleen specializes in strategy development across multiple therapeutic areas – focusing on aligning a study’s design with top enrolling investigators in the right countries.

Using PSI’s INTELIA platform, a machine-learning-powered system for data-driven feasibility and enrollment forecasting that models and compares hundreds of country and site combinations, their budgets and probability of success, Colleen develops recommendations for optimized enrollment in line with each sponsor’s key objectives.

As an Associate Director, Colleen provides leadership for global feasibility and site identification activities for both pre- and post-award opportunities and projects.

Meet us at ASH 2023

Vince, Rhonda, Colleen, and the rest of our team are excited to discuss your upcoming oncology study at ASH 2023. Click here to reserve your spot today.

If you would like to work with PSI as an investigator, submit an inquiry through our contact form here.

ASH 2023: PSI Team Spotlight Read More »

SNMMI 2023 Annual Meeting: PSI Team Spotlight

The SNMII 2023 Annual Meeting is coming up June 24 – 27, and our team at PSI is excited to join the conversation with nuclear medicine and molecular imaging sponsors and partners like you. The team will be walking the floor, ready to speak with you about your upcoming study. Schedule some time to speak with PSI experts helping to support innovators across the globe. Meet two of our experts packing their bags for Chicago below!

Dylan Stoy
Associate Director, Therapeutic Strategy

Dylan Stoy, PSI’s Therapeutic Strategy Director, is dedicated to conducting and executing better clinical studies in PSI’s core therapeutic areas. Dylan has worked in radiopharmaceutical research for about 9 years, with research interests in targeted drug delivery systems and optimizing the conduct of studies. Dylan has overseen radiopharmaceutical research from various roles including onsite research, design and trial conduct, clinical operations oversight, project management, and therapeutic strategy.

Dylan and his team are devoted to making participation for sites and patients in complex radiopharmaceutical studies more attainable and ensuring that PSI teams are highly trained and equipped to handle any challenges your program might encounter. Dylan works closely with the core business units within PSI, overseeing research throughout the study lifecycle, providing strategic leadership to our teams and collaborators (both internally and externally), and delivering corporate-wide trainings to make PSI your full-service CRO for all things radiopharmaceutical development.

 
Wes Ross with teal circle border

Wes Ross
Site Support Specialist

Wes Ross, Site Support Specialist, is one of PSI’s keys to addressing the complexities that lie in the conduction of radiopharmaceutical trials. Wes has a BS in Radiologic Sciences and an AS in Radiology and is also a licensed nuclear medicine technologist with over 22 years of hands-on experience working in the field. He has worked as a nuclear medicine technologist, working on the development and oversight of nuclear medicine research, and has worked in the creation of testing and controls for digital PET/CT technology. Wes uses his breadth of experience to drive PSI ahead of the curve for conducting successful research in the industry, developing new and exciting ways to get radiopharmaceutical studies up and running.

Wes manages the site qualification process for imaging studies and manufacturing radiopharmaceutical products, oversees the process of image acquisition and quality control, and is responsible for training trial sites, project teams, and vendors to deliver meaningful research in the requirements and strategies for the programs he works on. Wes works closely with other core units both within PSI and sponsor companies, such as project management, clinical operations, CMC, and supply chain to help design studies, project plans, and training materials in the radiopharmaceutical space.

Meet us at SNMMI 2023

Dylan, Wes, and the rest of our team are excited to discuss your upcoming study at SNMMI 2023. Click here to reserve your spot today.

SNMMI 2023 Annual Meeting: PSI Team Spotlight Read More »

Chicago,Skyline,Aerial,Drone,View,From,Above,,City,Of,Chicago

ASCO 2023: PSI Team Spotlight

ASCO 2023 is coming up June 3 – 5, and our team at PSI is excited to join the conversation with oncology sponsors and partners like you. Stop by Booth #19020 for a chance (or schedule a meeting here) to speak with PSI experts helping to support oncology innovators across the globe. Meet our team members who are packing their bags for Chicago.

Vince Calderon with teal circle border

Vince Calderon
Director Project Management

Vince serves as a Director and supervisor of Project Management, overseeing PSI’s team of Project Management staff and several studies in oncology and hematology. Vince has been with PSI since December 2019, and is based in Texas. He has over 19 years’ clinical research experience, 15 years of project management experience, and has delivered 20+ oncology studies in both solid tumors and hematology-oncology.

Vince has professional affiliations with the Project Management Institute in the US and has been a certified Project Management Professional since 2012.

Emily Mcinturf with pink circle border

Emily McInturf
Director, Feasibility

Emily McInturf, Director Feasibility, has worked in the clinical research industry for the past 15 years. As a leader within PSI’s global feasibility team, Emily specializes in strategy development across multiple therapeutic areas – focusing on aligning a study’s design with top enrolling investigators in the right countries.

Using PSI’s INTELIA platform, a machine-learning-powered system for data-driven feasibility and enrollment forecast, Emily models and compares hundreds of country and site combinations, their budgets and probability of success, ultimately recommending the most optimal enrollment scenario in line with each sponsor’s key objectives.

As a Director, Emily provides oversight for global feasibility and site identification activities for both pre- and post-award opportunities and projects.

Rhonda Critchlow
Senior Director, Operations

Rhonda Critchlow, Senior Director of Therapeutic Strategy, currently oversees all of PSI’s core indications, and specializes in operational strategy within oncology and radiopharmaceuticals. With over 25 years of research experience, she provides valuable leadership and management working both regionally and globally.

Overseeing the therapeutic strategy department, which includes our Site Support Specialist, Rhonda brings guidance and oversight to specialty vendor management, patient recruitment and retention for our sponsors.

Prior to working at PSI, her experience includes working within oncology research as a Coordinator and Director, CRA, Clinical Trial Manager, Head of Monitoring and Vice President of Early Phase Oncology before joining PSI. Rhonda also has experience working with general radiology and nuclear medicine in large hospital organizations, providing valuable input for clinical development, study management and operational considerations.

Meet us at ASCO 2023

Vince, Emily, and the rest of our team are excited to discuss your upcoming oncology study at ASCO 2023. Click here to reserve your spot today.

ASCO 2023: PSI Team Spotlight Read More »